<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324282</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/33</org_study_id>
    <nct_id>NCT03324282</nct_id>
  </id_info>
  <brief_title>First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma</brief_title>
  <acronym>GCISAVE</acronym>
  <official_title>Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess efficacy (based on response rate) and safety (based on grade ≥ 3&#xD;
      severe adverse effects) of the combination Gemcitabine Cisplatin (GC) + anti-PD-L1 (avelumab)&#xD;
      in first-line treatment for locally advanced or metastatic urothelial bladder cancer&#xD;
      patients, after 6 cycles of treatment (or at 18 weeks if less than 6 cycles have been given,&#xD;
      or earlier if a second line treatment is needed, before this new anticancer treatment has&#xD;
      been started).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent results in cancer research highlight the importance of immune checkpoints in the&#xD;
      control of immune response and provide access to molecules interfering with the inhibited&#xD;
      immune response during the development of cancer. Drugs targeted against CTLA-4, PD-1 or&#xD;
      PD-L1 have shown efficacy in various tumor types. In locally advanced or metastatic&#xD;
      urothelial bladder cancer (MBC), the standard first-line treatment is the association of&#xD;
      Gemcitabine and Cisplatin (GC). Objective responses and prolonged objective responses have&#xD;
      been reported with monoclonal antibodies against PD-1 or PD-L1 in MBC patients after failure&#xD;
      of chemotherapy. Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal&#xD;
      antibody. Avelumab treatment did not show unexpected cross-toxicity with chemotherapy when&#xD;
      studied in phase I / II in patients with different tumor types. So the combination at full&#xD;
      doses of GC and avelumab seems appropriate.&#xD;
&#xD;
      The experimental treatment is a combination of GC and avelumab given for 6 cycles. The&#xD;
      duration of each cycle is 3 weeks (Gemcitabine: dose of 1000 mg/m2 as an intravenous infusion&#xD;
      over 30 minutes on Days 1 and 8 of each 21-day cycle; Cisplatin: dose of 70 mg/m2 as a slow&#xD;
      intravenous infusion over 2 to 4 hours on Day 1 of each 21-day cycle; Avelumab: 10 mg/kg body&#xD;
      weight administered Iv once every 3 weeks).&#xD;
&#xD;
      Patients who have received all scheduled treatments and whose disease has not progressed at&#xD;
      the end of treatment will enter into disease follow-up. During this follow-up period,&#xD;
      patients will have disease and safety assessments performed every 3 months. Patients will&#xD;
      remain in follow-up for up to 1 year from last dose of treatment and will have survival&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: objective response rate with RECIST 1.1 with GC + avelumab</measure>
    <time_frame>At the end of cycle 6 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: proportion of severe toxicity with GC + avelumab</measure>
    <time_frame>At the end of cycle 6 (each cycle is 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunological capacities in peripheral blood of GC alone and GC+avelumab groups</measure>
    <time_frame>During treatment and after the 6 cycles of treatment (EOT + 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific immunological toxicity documented and recorded using NCI CTCAE version 4.0</measure>
    <time_frame>At the end of cycle 6 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At 18 months in GC+avelumab treated patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 18 months in GC+avelumab treated patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GC+avelumab efficacy according to the expression of PD-L1 at the tumor site</measure>
    <time_frame>At the end of cycle 6 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GC+avelumab efficacy according to the immune infiltrate populations at the tumor level and/or the tumor surroundings</measure>
    <time_frame>At the end of cycle 6 (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Bladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A: GC + avelumab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: GC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)</description>
    <arm_group_label>Arm A: GC + avelumab group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC</intervention_name>
    <description>Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)</description>
    <arm_group_label>Arm A: GC + avelumab group</arm_group_label>
    <arm_group_label>Arm B: GC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated informed consent;&#xD;
&#xD;
          2. Male or female, age ≥18 years at time of informed consent signature;&#xD;
&#xD;
          3. Histological confirmed locally advanced (any T N2-3) or metastatic urothelial bladder&#xD;
             carcinoma, eligible to first-line treatment (previous neo adjuvant or adjuvant&#xD;
             treatment must have been given and stopped more than one year before);&#xD;
&#xD;
          4. Evidence of progressive disease in the previous 6 months, documented by chest and/or&#xD;
             abdominal CT-scan or MRI;&#xD;
&#xD;
          5. Measurable disease according to RECIST 1.1;&#xD;
&#xD;
          6. Karnofsky index ≥ 70%;&#xD;
&#xD;
          7. Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumour&#xD;
             specimen (infiltrative urothelial bladder carcinoma or metastasis) collected within 12&#xD;
             months before Cycle 1 Day 1;&#xD;
&#xD;
          8. At least 3 weeks since the end of prior local intravesical treatment (BCG-therapy or&#xD;
             ametycine) with resolution of all treatment-related toxicity to grade ≤1 (NCI CTCAE&#xD;
             4.0);&#xD;
&#xD;
          9. Palliative local treatment is allowed if performed ≥ 2 weeks prior study entry for&#xD;
             radiotherapy, cimentoplasty or minor surgery, and ≥4 weeks for major surgery;&#xD;
&#xD;
         10. Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               1. Absolute White Blood Cells count (WBC) ≥ 2000 cells/mm3&#xD;
&#xD;
               2. Absolute Neutrophils count (ANC) ≥ 1500 cells/mm3&#xD;
&#xD;
               3. Platelets ≥100 000 cells/mm3&#xD;
&#xD;
               4. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               5. Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and&#xD;
                  ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with&#xD;
                  documented metastatic disease to the liver).&#xD;
&#xD;
               6. Calculated creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
         11. Women of childbearing potential must have a negative serum βHCG or urine pregnancy&#xD;
             test within 7 days prior to initiation of treatment; both sexually active females and&#xD;
             males (and their female partners) patients must agree to use two methods of effective&#xD;
             contraception one of them being a barrier method, or to abstain from sexual activity&#xD;
             during the study, for at least 3 months after the last administration of study&#xD;
             treatment;&#xD;
&#xD;
         12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures;&#xD;
&#xD;
         13. Patient affiliated to a social security system or beneficiary of the same.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other prior first-line therapy;&#xD;
&#xD;
          2. Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer&#xD;
             treatment; focal radiation therapy less than 14 days prior to the first day of the&#xD;
             first cycle;&#xD;
&#xD;
          3. Other invasive malignancy within 3 years (except for locally curable cancers that have&#xD;
             been apparently cured, such as basal or squamous cell skin cancer, superficial bladder&#xD;
             cancer, or carcinoma in situ of the prostate, cervix or breast); Patient with low risk&#xD;
             prostate cancer (defined as Stage T1/T2a, Gleason score ≤ 7 and PSA ≤ 10ng/mL) who are&#xD;
             treatment-naïve and undergoing active surveillance are eligible;&#xD;
&#xD;
          4. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety&#xD;
             risk based on investigator's judgment are acceptable;&#xD;
&#xD;
          5. Symptomatic central nervous system (CNS) metastases or untreated CNS metastases&#xD;
             requiring concurrent treatment;&#xD;
&#xD;
          6. Clinically significant (i.e. active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart&#xD;
             Association Classification Class II), or serious cardiac arrhythmia requiring&#xD;
             medication;&#xD;
&#xD;
          7. Uncontrolled adrenal insufficiency;&#xD;
&#xD;
          8. Active chronic liver disease;&#xD;
&#xD;
          9. Other severe acute or chronic medical conditions including colitis, inflammatory bowel&#xD;
             disease, pneumonitis, pulmonary fibrosis or psychiatric conditions including recent&#xD;
             (within the past year) or active suicidal ideation or behavior; or laboratory&#xD;
             abnormalities that may increase the risk associated with study participation or study&#xD;
             treatment administration or may interfere with the interpretation of study results&#xD;
             and, in the judgment of the investigator, would make the patient inappropriate for&#xD;
             entry into this study;&#xD;
&#xD;
         10. Active infection requiring systemic antibiotic;&#xD;
&#xD;
         11. Vaccination within 4 weeks of the first dose of avelumab and while on trials is&#xD;
             prohibited except for administration of inactivated vaccines;&#xD;
&#xD;
         12. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal,&#xD;
             inhaled, topical steroids, or local steroid injection (e.g., intra-articular&#xD;
             injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone&#xD;
             or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT&#xD;
             scan premedication);&#xD;
&#xD;
         13. Major surgery less than 28 days prior to the first day of the first cycle. Minor&#xD;
             surgery less than 14 days prior to the first day of the first cycle;&#xD;
&#xD;
         14. Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory&#xD;
             agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid&#xD;
             diseases not requiring immunosuppressive treatment are eligible;&#xD;
&#xD;
         15. History of primary immunodeficiency;&#xD;
&#xD;
         16. History of organ transplant including allogeneic stem-cell transplantation;&#xD;
&#xD;
         17. Known prior severe hypersensitivity to investigational product or any component in its&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies (NCI CTCAE v4.03 Grade ≥ 3);&#xD;
&#xD;
         18. Women who are pregnant or lactating;&#xD;
&#xD;
         19. Known history of testing positive for HIV or known acquired immunodeficiency syndrome;&#xD;
&#xD;
         20. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus&#xD;
             ribonucleic acid (HCV RNA) indicating acute or chronic infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain RAVAUD, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain RAVAUD, MD. PhD</last_name>
    <phone>+33 (0)5 56 79 58 08</phone>
    <email>alain.ravaud@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine THIERY VUILLEMIN</last_name>
      <phone>+33 (0)3 81 66 87 05</phone>
      <email>a.thieryvuillemin@mac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain RAVAUD</last_name>
    </contact>
    <contact_backup>
      <phone>+33 (0)5 56 79 58 08</phone>
      <email>alain.ravaud@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guilhem ROUBAUD</last_name>
      <phone>+33 (0)5 24 07 19 12</phone>
      <email>G.Roubaud@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie COQUAN</last_name>
      <phone>+33 (0)2 31 45 50 02</phone>
      <email>coque@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude FLECHON</last_name>
      <phone>+33 (0)4 78 78 26 43</phone>
      <email>aude.flechon@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenaëlle GRAVIS</last_name>
      <phone>+33 (0)4 91 22 37 40</phone>
      <email>gravisg@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric ROLLAND</last_name>
      <phone>+33 (0)2 40 67 99 76</phone>
      <email>frederic.rolland@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane OUDARD</last_name>
      <phone>+33 (0)1 56 09 34 47</phone>
      <email>stephane.oudard@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis, AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane CULINE</last_name>
      <phone>+33 (0)1 42 49 42 47</phone>
      <email>stephane.culine@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc TOURANI</last_name>
      <email>Jean-Marc.TOURANI@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BARTHELEMY</last_name>
      <phone>+33 (0)3 88 11 67 28</phone>
      <email>Philippe.barthelemy@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU</last_name>
      <phone>+33 (0)5 31 15 51 52</phone>
      <email>Chevreau.Christine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yohann LORIOT</last_name>
      <phone>+33 (0)1 42 11 52 76</phone>
      <email>yohann.loriot@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti PD1</keyword>
  <keyword>Bladder carcinoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Immunological monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

